Alongside friends, family, local and academic authorities, the Graduation Day ceremony bestowed post-graduate diplomas to 21 female and 7 male students. Building upon the strong multidisciplinary background of each student, the 2024 class brought together those with master’s degrees in Biology, Medical, Pharmaceutical, and Veterinary Biotechnologies, and Pharmacy and Pharmaceutical sciences.
What began on 6 November 2023, the 8-month-long blended training program included classroom lessons, laboratory activities, and individual internships. Several of the 15 companies from the pharmaceutical sector that hosted the internships will continue their collaborative working relationship with PharmaTech Academy students. Spanning across Italy, the 15 companies included Anemocyte S.r.l., Dompé Farmaceutici S.p.A., Eurofins Biolab Srl, Genetics S.p.A., Istituto Biochimico Italiano S.p.A. (IBI Lorenzini), Innovavector S.r.l., IRBM S.p.A., Italfarmaco S.p.A., Nouscom Srl, Officine Innovazione S.r.l. SB, PBL srl, Sanofi S.r.l., Nuova Ompi Srl Unipersonale (Stevanato Group), Takis S.r.l., and Thermo Fisher Scientific Inc.
The growing interest and success of the training program have led to an increased enrollment capacity with a maximum of 40 eligible students for the 2024-25 academic year. Now open, the call for applicants encourages holders of a master’s in most STEM disciplines to apply. Ample funding from the National Center ensures that all 40 students will receive scholarships to cover the entire cost of the course. With a budget of 2M euros dedicated to the PharmaTech Academy initiative, the National Center allocates 46% to infrastructure, 28% to education, and the remaining to scholarships.
